九号公司：智能短交通+机器人领域的全能玩家。 公司以"简化人和物的移动"为使命，通过核心技术的复用和升级打造"智能短交通+服务机器人"的平台 化业务生态，形成了电动平衡车、电动滑板车、智能两轮电动车、E-Bike、全地形车、割草机器人和配 送机器人等丰富的产品线。2024 年公司营收/归母净利润分别为142 亿/11 亿（ 同比+39%/+81%），两 轮电动车已成为公司的营收主体（占比51%），割草机器人、全地形车等逐步开始放量，业绩潜力加速 释放可期。 稳中有进-两轮车：高端智能化龙头，享行业结构性升级机遇 当前电动两轮车消费需求呈现明显的高端智能化导向，九号电动车自诞生以来便聚焦智能化&中高端 化，在品牌认知度、购买优先度和智能化性能等维度均行业领先，2024 年九号以60 万+销量独占4000 元以上市场第一梯队。 同时，新国标的实施对车辆性能提出更高要求，市场份额有望向有技术研发实力、规模和品牌优势的优 质厂家集中，公司有望充分受益。另外，公司依托两轮车智能化基因与Segway 品牌优势进军全球E- Bike 市场，进一步实现短交通全场景覆盖。 二次腾飞-服务机器人：抢滩机器人新赛道，助力成长 公司 ...

Core Insights - Cognition Therapeutics, Inc. conducted a positive end-of-Phase 2 meeting with the FDA regarding zervimesine (CT1812) for Alzheimer's disease treatment [1][2] - The SHINE Study demonstrated safety and tolerability, meeting its primary endpoints with 153 participants [4] - Zervimesine has been adopted as the United States Adopted Name (USAN) for CT1812 [3] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [6] - The company is advancing zervimesine through various clinical studies, including ongoing trials for dementia with Lewy bodies and early Alzheimer's disease [6] Study Details - The SHINE Study was a double-blind, placebo-controlled Phase 2 trial that enrolled 153 adults with mild-to-moderate Alzheimer's disease, assessing cognitive and functional changes [4] - The study received approximately $30 million in grant support from the National Institute on Aging [5] Drug Mechanism - Zervimesine is an investigational oral medication that targets the toxic effects of Aβ and ɑ-synuclein proteins associated with neurodegenerative diseases [2][6] - The drug aims to slow disease progression and improve the quality of life for patients suffering from Alzheimer's and dementia with Lewy bodies [2]

Key Takeaways SMMT surged after reports of AstraZeneca exploring a $15 billion licensing deal for ivonescimab. The deal may include billions upfront, with milestone payments tied to Ivonescimab's progress. Ivonescimab showed superiority over Keytruda and Tevimbra in late-stage NSCLC trials.Shares of clinical-stage company Summit Therapeutics (SMMT) rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca (AZN) is in discussions with the company for a po ...

平时在终端敲代码，用的比较多的还是 Vim，但有时会被 Vim 的 反人类键位 搞到想砸键盘？ VSCode 好用是 好 用，但很多简单的修改根本用不上，而且 用 VSCode 写着写着，鼠标点得手酸，扩展装多了还臃肿～ 尝试 Neovim 想走极客路线，结果一头扎进插件地狱，光配个 LSP 都能折腾一下午？ 今天必须安利一款不整那些花里胡哨又轻巧的 编辑器 -- Helix 。 Helix 是一款受 Kakoune 和 Neovim 启发的现代终端编辑器，用 Rust 编写。 Helix 不仅 智能高效、轻量快速 ，还支持 语法树级别的代码理解 ！ 核心功能： 支持多光标编辑 -- Helix 把「多光标」当成基本操作单位，很多编辑命令天生就可以同时作用在多个地方，灵感来自 Kakoune。 语法感知编辑 -- 通过集成 tree-sitter，可以选中一个函数、一段注释、一个 JSON 对象，而不仅仅是字符块。这也让语法高亮、缩进和跳 转更加可靠。 内建语言服务器支持 -- 自动补全、跳转定义、诊断报错、查文档，全都开箱即用，不用你再装插件配置 LSP。 内置模糊搜索器 -- 无论是文件跳转、代码符号查找 ...

Core Insights - Vimeo, Inc. has appointed Rose Frawley as Chief People Officer, focusing on global talent strategy and organizational development [1][2] - Frawley's experience includes over 20 years in human resources, with a strong background in building high-performing teams in technology and data companies [2] - The company emphasizes a people-first strategy, aiming to cultivate a culture of trust and engagement among employees [1][3] Company Overview - Vimeo is recognized as the largest private video network globally, serving millions of users and facilitating billions of video views each month [4] - The platform aims to provide innovative video experiences, catering to a diverse community from creative storytellers to large corporate teams [4]

PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer’s Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. Christopher van Dyck, ...

Core Insights - Merck (MRK) has reached a significant support level, making it an attractive option for investors from a technical standpoint, with the stock breaking through its 50-day simple moving average (SMA) since early June, indicating a potential short-term bullish trend [1][2] Company Strengths - Keytruda, a PD-L1 inhibitor, is Merck's biggest strength, accounting for around 50% of the company's pharmaceutical sales and driving steady revenue growth [3][4] - The company is pursuing innovative strategies for Keytruda's long-term growth, including combinations with other immuno-oncology drugs and a personalized mRNA therapeutic cancer vaccine in partnership with Moderna [5][6] - Merck's phase III pipeline has almost tripled since 2021, positioning the company to launch around 20 new vaccines and drugs over the next few years, including the 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair [8][9] Company Weaknesses - Merck faces headwinds, including lowered 2025 guidance, concerns about Keytruda's long-term performance, and weak sales of Gardasil in China, leading to a temporary halt in shipments [2][13] - The company is heavily reliant on Keytruda, with concerns about its ability to grow its non-oncology business ahead of the drug's patent expiration in 2028 [11] - Competitive pressure for Keytruda is expected to increase, with potential competition from Summit Therapeutics' ivonescimab [12] Sales Performance - Gardasil sales are declining in China due to sluggish demand trends, resulting in elevated inventory levels and a decision to halt shipments [13][14] - Despite challenges in China, Gardasil remains strong in other major regions, including the United States [13] Stock Valuation - Merck's shares have lost 17.7% this year, underperforming the industry and the S&P 500 [15][16] - The company's shares trade at a price/earnings ratio of 8.63, lower than the industry average of 14.79 and its 5-year mean of 12.86, indicating attractive valuation relative to the industry [18] Analyst Outlook - Analysts have lowered EPS estimates for both 2025 and 2026 over the past 60 days, reflecting a pessimistic outlook for the stock [21][25] - Short-term investors may consider selling MRK stock due to several near-term headwinds, while new products like Capvaxive and Winrevair have potential for significant long-term revenues [24][25][26]

Core Insights - Cognition Therapeutics, Inc. is advancing zervimesine (CT1812) into a Phase 3 program for mild-to-moderate Alzheimer's disease and has filed for breakthrough therapy designation for dementia with Lewy bodies (DLB) [1][2] Group 1: Clinical Development - An end-of-Phase 2 meeting with the FDA is scheduled for July 9, 2025, to discuss the Phase 2 'SHINE' study results and plans for a Phase 3 program for zervimesine in Alzheimer's disease [1] - The company is also progressing with an expanded access program for zervimesine in DLB, which has garnered high interest from former SHIMMER study participants [3] Group 2: Drug Information - Zervimesine (CT1812) is an investigational oral medication aimed at treating neurodegenerative diseases, specifically Alzheimer's disease and DLB, by potentially interrupting the toxic effects of protein buildup in the brain [4] - The drug has been generally well tolerated in clinical studies to date [4] Group 3: Company Overview - Cognition Therapeutics, Inc. focuses on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and has completed Phase 2 studies for zervimesine in multiple conditions [6]

Core Viewpoint - Cognition Therapeutics, Inc. is advancing its investigational drug zervimesine (CT1812) for the treatment of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB), with an end-of-Phase 2 meeting scheduled with the FDA to discuss Phase 2 study results and plans for a Phase 3 program [1][2][8] Group 1: Clinical Development - The company will hold an end-of-Phase 2 meeting with the FDA on July 9, 2025, to review the Phase 2 'SHINE' study results of zervimesine in Alzheimer's disease [1] - Cognition is also moving forward with plans for a registrational program for DLB based on positive results from the Phase 2 'SHIMMER' study [2] - An expanded access program for zervimesine in DLB is underway, with high interest from former SHIMMER participants [3] Group 2: Drug Information - Zervimesine (CT1812) is an oral, once-daily investigational drug targeting neurodegenerative diseases, specifically Alzheimer's and DLB, by potentially interrupting the toxic effects of harmful proteins in the brain [4] - The drug has been generally well tolerated in clinical studies to date [4] - The USAN Council has adopted zervimesine as the official name for CT1812 [5] Group 3: Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6] - The company has completed Phase 2 studies for zervimesine in multiple conditions, including DLB and Alzheimer's disease, and is currently conducting an ongoing Phase 2 study in early Alzheimer's disease [6]

2025.06. 24 本文字数：2380，阅读时长大约4分钟 作者 | 第一财经 林志吟 根据中国疾控最新发布的全国急性呼吸道传染病哨点监测情况，第24周（2025年6月9日—6月15 日），住院严重急性呼吸道感染病例呼吸道样本检测阳性率前三位病原体中，呼吸道合胞病毒 （RSV）赫赫在列。 病毒危害 呼吸道合胞病毒是一种常见的呼吸道病毒，主要通过呼吸道飞沫与密切接触传播。 深圳市妇幼保健院新生儿科主任杨传忠对第一财经记者表示，呼吸道合胞病毒感染以呼吸道症状为 主，临床典型表现为喘息、喘憋（呼吸困难），属于喘息性支气管炎范畴，部分患儿可伴发热，严重 者可能出现呼吸衰竭、心功能衰竭等危及生命的并发症。 尽管任何年龄段人群均可能感染呼吸道合胞病毒，但其在婴儿，特别是早产儿、患有慢性肺病或先天 性心脏病的儿童以及老人中，病情通常更为严重。 "早产儿由于器官发育不完善，感染呼吸道合胞病毒后风险更高，例如，32周到40周是肺泡快速发 育阶段（每日新增约20万到30万个肺泡），而早产儿肺泡数量不足、功能不成熟，感染后易引发呼 吸衰竭，需呼吸机支持，甚至继发心力衰竭。"杨传忠说，足月儿因肺泡发育完整，感染后耐受性更 强，6 ...